The Global Plant-based Vaccines Market, by Vaccine Type (Bacterial Vaccines, Viral Vaccines, Parasite Vaccines, and Others), by Source (Tobacco Plant, Maize, Potato, and Others), by Application (Influenza, Zika Virus Disease, Ebola Virus Disease, Poultry Diseases, and Others), and by Region (North America, and Europe) is estimated to be valued at US$ 927.0 million in 2020, and is projected to exhibit a CAGR of 11.7% over the forecast period (2020 – 2026).
Plant-based vaccines are increasingly being studied as a cheap alternative to the conventional vaccine in terms of efficiency, production time, and immune system. Plant-based vaccines market includes few market player and increasing number of start-up and research institutes, which are focused on R&D activities to develop treatment therapies for various infectious disease indications such as flu, dengue, norovirus, and avian influenza H5N1; based on new plant-based source vaccine. For instance, in August 2018, researchers from Arizona State University’s (ASU) Biodesign Institute, developed a norovirus vaccine from tobacco plant. Genetic engineering has allowed researchers to transfer specific genes from tobacco plant in designing plant-based vaccine for norovirus. Plant-based vaccine safe and effective for use against various infectious diseases as it activates patient’s immune system. In June 2018, researchers from the University of Nottingham, Malaysia, announced a project to develop plant-based vaccine for treatment of dengue fever, caused by Aedes genus mosquitoes.
The researchers produced vaccine antigen within the tobacco plant, which can neutralize dengue virus. Moreover, utilization of plant source in virus production offers new platform to provide vaccine that can be taken orally, as currently available vaccines are mostly given intravenously. Other than tobacco plant, researchers are also working on edible plant species such as lettuce for future vaccine production. Successful completion of research studies would offer a safe and cost effective treatment to prevent dengue. For instance, according to the Journal of Botany: March 2016, the dengue virus vaccine targeting dengue-3 serotype polyprotein (DENV3prM/E) was produced in Lactuca sativa (lettuce) through a chloroplast transformation. It is further concluded that, lettuce is an excellent host for agroinfiltration with deconstructed viral vectors.
Browse 20 Market Data Tables and 14 Figures spread through 128 Pages and in-depth TOC on ‘Global Plant-based Vaccines Market, by Vaccine Type (Bacterial Vaccines, Viral Vaccines, Parasite Vaccines, and Others), by Source (Tobacco Plant, Maize, Potato, and Others), by Application (Influenza, Zika Virus Disease, Ebola Virus Disease, Poultry Diseases, and Others), and by Region (North America, and Europe) - Global Forecast to 2026’
To know the latest trends and insights prevalent in the plant-based vaccines market, click the link below:
Key players in the global plant-based vaccines market are focused on in-organic growth strategies such as strategic collaborations and acquisition to harness R&D capabilities in development of new plant-based vaccines. For instance, in June 2016, The Texas A&M University System (including Texas A & M University AgriLife Research and the Texas A & M Institute of Infectious Animal Diseases (IIAD)), entered into agreement with iBio, Inc., and its subsidiary, iBio CMO LLC for a collaborative program in plant-produced pharmaceuticals. The collaboration is expected to leverage R&D resources of the research institute with the commercial therapeutics and vaccine development and manufacturing capabilities of iBio. The goal of the collaboration is to rapidly develop and test cost-effective, commercial, therapeutic, and vaccine solutions against various diseases such as influenza and Ebola. Furthermore, in July 2013, Medicago, Inc., a Canada-based biopharmaceutical company, entered into a definitive agreement with Mitsubishi Tanabe Pharma Corporation, whereby Medicago was acquired by Mitsubishi with 60% share in Medicago, Inc. 40% of the shares are currently held by Philip Morris Investments B.V.
Key Takeaways of the Global Plant-based Vaccines Market: